Literature DB >> 19141573

Validation of a simple activity participation measure for rheumatoid arthritis clinical trials.

T Li1, G Wells, R Westhovens, P Tugwell.   

Abstract

OBJECTIVE: To examine the validity, reliability and sensitivity to change of the Activity Participation Questionnaire (APaQ), a simple measure of activity participation for patients with RA.
METHODS: The questionnaire contained two items: (i) number of days in the past month of being unable to perform one's usual activities because of RA; and (ii) a score measuring how often one's usual activities could be completed. The APaQ was administered to 1043 RA patients in two clinical trials of abatacept. Construct validity was evaluated by examining changes from baseline in activity scores by clinical response measured by the European League Against Rheumatism (EULAR) and ACR criteria and minimal disease activity (MDA) state and by correlations with patient-reported outcome measures of physical function, disease activity, pain and fatigue at study end-point. Internal consistency, test-retest reliability and sensitivity to change were assessed.
RESULTS: Both activity participation items were significantly associated with levels of EULAR and ACR response and the achievement of MDA state (P < 0.0005 for all comparisons). Moderate correlations with patient-reported outcomes were consistently found (correlations 0.5-0.6). Cronbach's alpha was 0.7 indicating good internal consistency, the intraclass correlation coefficient of 0.6 suggesting acceptable test-retest reliability. Sensitivity to change was demonstrated by the treatment differences and the standardized response mean (0.39 and 0.30) for the two activity items.
CONCLUSION: The APaQ is a simple, reliable and valid measure of patient activity, which is sensitive to change, suggesting its suitability for use in clinical trials.

Entities:  

Mesh:

Year:  2009        PMID: 19141573     DOI: 10.1093/rheumatology/ken448

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

1.  Silibinin Improves the Effects of Methotrexate in Patients with Active Rheumatoid Arthritis: Pilot Clinical Study.

Authors:  Saad Abdulrahman Hussain; Ahmed Hashem Mortada; Nazar Abdulateef Jasim; Faiq Isho Gorial
Journal:  Oman Med J       Date:  2016-07

2.  The efficacy and safety of abatacept in rheumatoid arthritis.

Authors:  Rene Westhovens; Patrick Verschueren
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-04       Impact factor: 5.346

3.  Development and validation of a short form of the valued life activities disability questionnaire for rheumatoid arthritis.

Authors:  Patricia P Katz; Diane C Radvanski; Diane Allen; Steven Buyske; Samuel Schiff; Anagha Nadkarni; Lisa Rosenblatt; Ross Maclean; Afton L Hassett
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-12       Impact factor: 4.794

4.  Do patient-reported outcome measures cover personal factors important to people with rheumatoid arthritis? A mixed methods design using the International Classification of Functioning, Disability and Health as frame of reference.

Authors:  Mona Dür; Michaela Coenen; Michaela Alexandra Stoffer; Veronika Fialka-Moser; Alexandra Kautzky-Willer; Ingvild Kjeken; Răzvan Gabriel Drăgoi; Malin Mattsson; Carina Boström; Josef Smolen; Tanja Alexandra Stamm
Journal:  Health Qual Life Outcomes       Date:  2015-02-25       Impact factor: 3.186

5.  Usefulness of patients-reported outcomes in rheumatoid arthritis focus group.

Authors:  Jenny Amaya-Amaya; Diana Botello-Corzo; Omar-Javier Calixto; Rolando Calderón-Rojas; Aura-Maria Domínguez; Paola Cruz-Tapias; Gladis Montoya-Ortiz; Ruben-Dario Mantilla; Juan-Manuel Anaya; Adriana Rojas-Villarraga
Journal:  Arthritis       Date:  2012-09-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.